Marathon Petroleum Corp vs Zoetis Inc — how do they compare? Marathon Petroleum Corp trades at $336.13 (market cap $89.95B), while Zoetis Inc trades at $75.11 (market cap $30.92B). The key difference: Marathon Petroleum Corp is far larger — about 2.9× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| MPC | ZTS | |
|---|---|---|
Market Cap | $89.95B | $30.92B |
Sector | Energy | Health |
52-Week High | $336.42 | $156.76 |
52-Week Low | $159.11 | $71.91 |
Enterprise Value | $116.48B | $38.49B |
Dividend Yield | 1.25% | 2.83% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoetis (ZTS) trades at $72.66, down 5.92% amid a bearish technical signal and recent earnings pressure. The stock is near its 52-week low after Piper Sandler cut its price target to $80.00 on August 11, 2026. Despite strong profitability with a net margin of 27.69% and ROE of 64.91%, Q2 2026 revenue missed estimates, and the company reduced its 2026 outlook due to softer pet healthcare demand. Cash flow improved in 2025 with net cash flow of $325 million, but debt-to-asset ratio remains elevated at 46.14%.
The outlook is cautious with near-term headwinds in companion animal markets, but long-term fundamentals remain solid given the company's leading position in animal health. Risks include competitive pressures and a class action lawsuit. Analyst consensus is a Buy with a $95.00 price target, implying significant upside if execution improves.
Trailing returns across standard periods
Latest headlines on both assets
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →